# EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

> **NCT04516161** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1180 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)

## Key facts

- **NCT ID:** NCT04516161
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-03
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 1180 (ACTUAL)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516161, "EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04516161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*